This two-day event on November 6-7, is free to anyone affected by, or interested in, neuroblastoma.
Neuroblastoma is a difficult to treat childhood cancer that strikes children, on average, at only two years of age. Children with resistant or relapsed disease, after current treatment options are exhausted, have very poor survival rates.
The Covid-19 pandemic has created many challenges for research institutions and advocacy organizations, one of which is the cancellation of numerous scientific and educational conferences that focus on neuroblastoma. This challenge also provided Solving Kids' Cancer (SKC), the Children’s Neuroblastoma Cancer Foundation (CNCF), and Solving Kids Cancer-UK (SKC-UK) the opportunity to think globally, extend their collective ambitions and work with international partners to develop and host the Neuroblastoma Parent Global Symposium (NPGS), the first of its kind for the global neuroblastoma community.
“Connecting families with cancer care providers and researchers as well as with other families is invaluable during a time when the cancer journey can be so isolating.” said Scott Kennedy, Executive Director of Solving Kids’ Cancer. “Pivoting to a virtual format allows for international expansion so that more families have access to these valuable resources. We are excited about building and serving a global community of families, clinicians, and researchers.”
The program development is being led by the NPGS Steering Committee, chaired by Dr. Daniel Morgenstern, Director of the New Agent and Innovative Therapy Program at SickKids, Toronto. The committee includes clinicians and researchers of international repute to advise on the scope and content of the program, which will include 25 virtual sessions of credible and reliable patient/parent education about neuroblastoma with information for the newly diagnosed, overview of international frontline treatments, best practices in clinical care, relapse options, psycho/social issues, drug development and emerging therapies, survivor issues and bereavement support.
nbparentsymposium dot com
About the Nonprofit Partners
Solving Kids’ Cancer
Solving Kids’ Cancer is not just our name, it’s our mission. We focus on aggressive childhood cancers with low survival rates because Every Kid Deserves to Grow Up.
Solving Kids' Cancer helps accelerate new clinical trials of next-generation treatments including immunotherapy, biomarker-based targeted agents, and new combination therapies through research advocacy, with an understanding of the childhood cancer research landscape and current unmet needs, to wisely invest in innovative projects.
Children’s Neuroblastoma Cancer Foundation
The Children’s Neuroblastoma Cancer Foundation (CNCF) is the premier source for neuroblastoma information and resources (nbparentsymposium.com). Comprised of families just like yours, we are committed to finding a cure for neuroblastoma through research, education, awareness and advocacy.
Solving Kids’ Cancer UK
Solving Kids’ Cancer UK (solvingkidscancer.org) is a parent-led charity, its vision is a future where no child dies of neuroblastoma or suffers due to its treatment. As part of its mission Solving Kids’ Cancer initiates and funds innovative clinical research to provide children with the best and most promising new therapies available closer to home. Solving Kids’ Cancer research focus is on clinical trials, seeking to explore new ways of treating neuroblastoma, providing hope and options for children and their families now as well as building on the scientific understanding of this disease for children in the future.
Neuroblastoma is an embryonal tumor that develops from specialized nerve cells left behind from a baby’s development in the womb. Around 90% of neuroblastoma cases occur in children younger than 5 years of age, with a median age at diagnosis of 19 months. It is the most common cancer in infants, accounting for 20%-30% of all cancer diagnoses in the first year of life. Neuroblastoma has one of the lowest survival rates of all childhood cancers, with only 68% of children surviving for five years, versus 83% for all childhood cancers combined.